ReviewBritish journal of pharmacology2007
Cardiovascular gene therapy: current status and therapeutic potential.
Review in British journal of pharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 90 citations in OpenAlex.
- Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer.Gene therapy · 2009Trial
- Targeted Delivery of mRNA to the Heart via Extracellular Vesicles or Lipid Nanoparticles.Journal of extracellular vesicles · 2026Article
- Article
- Unlocking the promise of mRNA therapeutics.Nature biotechnology · 2022Review
- Current Advances in RNA Therapeutics for Human Diseases.International journal of molecular sciences · 2022Review
- Cyclic adenosine monophosphate regulates connective tissue growth factor expression in myocardial fibrosis after myocardial infarction.The Journal of international medical research · 2021Article
- Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial.Molecular therapy. Methods & clinical development · 2020Article
- Hepatocyte growth factor intervention to reduce myocardial injury and improve cardiac function on diabetic myocardial infarction rats.European journal of histochemistry : EJH · 2020Article
- Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes.Nature communications · 2019Article
- Modified VEGF-A mRNA induces sustained multifaceted microvascular response and accelerates diabetic wound healing.Scientific reports · 2018Article
- Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction.International journal of nanomedicine · 2017Article
- Cardiac Regeneration using Growth Factors: Advances and Challenges.Arquivos brasileiros de cardiologia · 2016Review
- Inhibition of intimal hyperplasia via local delivery of vascular endothelial growth factor cDNA nanoparticles in a rabbit model of restenosis induced by abdominal aorta balloon injury.Experimental and therapeutic medicine · 2015Article
- Efficient transduction of vascular smooth muscle cells with a translational AAV2.5 vector: a new perspective for in-stent restenosis gene therapy.Gene therapy · 2013Article
- Mechanistic, technical, and clinical perspectives in therapeutic stimulation of coronary collateral development by angiogenic growth factors.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Review
- Anchoring of self-assembled plasmid DNA/anti-DNA antibody/cationic lipid micelles on bisphosphonate-modified stent for cardiovascular gene delivery.International journal of nanomedicine · 2013Article
- Gene targeting in ischemic heart disease and failure: translational and clinical studies.Biochemical pharmacology · 2013Review
- Overexpression of endothelial nitric oxide synthase improves endothelium-dependent vasodilation in arteries infused with helper-dependent adenovirus.Human gene therapy · 2012Article
- Cardiovascular surgery for realization of regenerative medicine.General thoracic and cardiovascular surgery · 2012Review
- Gene delivery technologies for cardiac applications.Gene therapy · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene therapy is emerging as a potential treatment option in patients suffering from a wide spectrum of cardiovascular diseases including coronary artery disease, peripheral vascular disease, vein graft failure and in-stent restenosis. Thus far preclinical studies have shown promise for a wide variety of genes, in particular the delivery of genes encoding growth factors such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) to treat ischaemic vascular disease both peripherally and in coronary artery disease. VEGF as well as other genes such as TIMPs have been used to target the development of neointimal hyperplasia to successfully prevent vein graft failure and in-stent restenosis in animal models. Subsequent phase I trials to examine safety of these therapies have been successful with low levels of serious adverse effects, and albeit in the absence of a placebo group some suggestion of efficacy. Phase 2 studies, which have incorporated a placebo group, have not confirmed this early promise of efficacy. In the next generation of clinical gene therapy trials for cardiovascular disease, many parameters will need to be adjusted in the search for an effective therapy, including the identification of a suitable vector, appropriate gene or genes and an effective vector delivery system for a specific disease target. Here we review the current status of cardiovascular gene therapy and the potential for this approach to become a viable treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.